Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

ConclusionsIn patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient.

http://link.springer.com/10.1007/s10072-018-3440-0

Source: Neurological Sciences - May 13, 2018 Category: Neurology Source Type: research